-
1
-
-
41549130929
-
Newer cytotoxic agents: Attacking cancer broadly
-
DOI 10.1158/1078-0432.CCR-07-2249
-
Teicher, B. A. Newer cytotoxic agents: attacking cancer broadly Clin. Cancer Res. 2008, 14, 1610-1617 (Pubitemid 351469444)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.6
, pp. 1610-1617
-
-
Teicher, B.A.1
-
2
-
-
34548405990
-
From cell signaling to cancer therapy
-
DOI 10.1111/j.1745-7254.2007.00697.x
-
Ding, J.; Feng, Y.; Wang, H.-Y. From cell signaling to cancer therapy Acta Pharmacol. Sin. 2007, 9, 1494-1498 (Pubitemid 47366694)
-
(2007)
Acta Pharmacologica Sinica
, vol.28
, Issue.9
, pp. 1494-1498
-
-
Ding, J.1
Feng, Y.2
Wang, H.-Y.3
-
3
-
-
0034788453
-
Tyrosine kinase inhibitors: From rational design to clinical trials
-
DOI 10.1002/med.1022
-
Traxler, P; Bold, G; Buchdunger, E; Caravatti, G; Furet, P; Manley, P; O'Reilly, T; Wood, J; Zimmermann, J. Tyrosine kinase inhibitors: from rational design to clinical trials Med. Res. Rev. 2001, 21, 499-512 (Pubitemid 32959239)
-
(2001)
Medicinal Research Reviews
, vol.21
, Issue.6
, pp. 499-512
-
-
Traxler, P.1
Bold, G.2
Buchdunger, E.3
Caravatti, G.4
Furet, P.5
Manley, P.6
O'Reilly, T.7
Wood, J.8
Zimmermann, J.9
-
4
-
-
77950573400
-
Through the "gatekeeper Door": Exploiting the active kinase conformation
-
references cited therein
-
Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "Gatekeeper Door": Exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681-2694 and references cited therein
-
(2010)
J. Med. Chem.
, vol.53
, pp. 2681-2694
-
-
Zuccotto, F.1
Ardini, E.2
Casale, E.3
Angiolini, M.4
-
5
-
-
77649204688
-
Selectively nonselective kinase inhibition: Striking the right balance
-
Morphy, R. Selectively nonselective kinase inhibition: Striking the right balance J. Med. Chem. 2010, 53, 1413-1437
-
(2010)
J. Med. Chem.
, vol.53
, pp. 1413-1437
-
-
Morphy, R.1
-
6
-
-
84855742534
-
-
According to a news release from the World Health Organization in 2003, the figure of 10 million new cases of cancer per year recorded in 2000 is expected to reach 15 million cases per year by 2020.
-
According to a news release from the World Health Organization in 2003, the figure of 10 million new cases of cancer per year recorded in 2000 is expected to reach 15 million cases per year by 2020 (http://www.who.int/ mediacentre/news/releases/2003/pr27/en/).
-
-
-
-
7
-
-
0000285504
-
ZD 1839, an epidermal growth factor tyrosine kinase inhibitors selected for clinical development
-
Woodburn, J. R.; Barker, A. J.; Gibson, K. H.; Ashton, S. E.; Wakeling, A. E. ZD 1839, an epidermal growth factor tyrosine kinase inhibitors selected for clinical development Proc. Am. Assoc. Cancer Res. 1997, 38, 6333
-
(1997)
Proc. Am. Assoc. Cancer Res.
, vol.38
, pp. 6333
-
-
Woodburn, J.R.1
Barker, A.J.2
Gibson, K.H.3
Ashton, S.E.4
Wakeling, A.E.5
-
8
-
-
0030779452
-
Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumor activity of novel quinazolines
-
Gibson, K. H.; Grundy, W.; Godfrey, A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlet, L.; Barker, A. J.; Brown, D. S. Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumor activity of novel quinazolines Bioorg. Med. Chem. Lett. 1997, 7, 2723-2727
-
(1997)
Bioorg. Med. Chem. Lett.
, vol.7
, pp. 2723-2727
-
-
Gibson, K.H.1
Grundy, W.2
Godfrey, A.3
Woodburn, J.R.4
Ashton, S.E.5
Curry, B.J.6
Scarlet, L.7
Barker, A.J.8
Brown, D.S.9
-
9
-
-
0037232108
-
Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents
-
DOI 10.1517/13543784.12.1.51
-
Laird, A. D.; Cherrington, J. M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents Expert Opin. Invest. Drugs 2003, 12, 51-64 (Pubitemid 36104643)
-
(2003)
Expert Opinion on Investigational Drugs
, vol.12
, Issue.1
, pp. 51-64
-
-
Laird, A.D.1
Cherrington, J.M.2
-
10
-
-
27144529359
-
Second-generation kinase inhibitors
-
DOI 10.1517/14728222.9.5.975
-
Klebl, B. M.; Müller, G. Second-generation kinase inhibitors Expert Opin. Ther. Targ. 2005, 9, 975-993 (Pubitemid 41488835)
-
(2005)
Expert Opinion on Therapeutic Targets
, vol.9
, Issue.5
, pp. 975-993
-
-
Klebl, B.M.1
Muller, G.2
-
11
-
-
0037232108
-
Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents
-
Laird, A. D.; Cherrington, J. M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents Expert Opin. Invest. Drugs 2003, 12, 51
-
(2003)
Expert Opin. Invest. Drugs
, vol.12
, pp. 51
-
-
Laird, A.D.1
Cherrington, J.M.2
-
12
-
-
57749188299
-
Targeting cancer with small molecule kinase inhibitors
-
Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39
-
(2009)
Nat. Rev. Cancer
, vol.9
, pp. 28-39
-
-
Zhang, J.1
Yang, P.L.2
Gray, N.S.3
-
13
-
-
36248944181
-
An integrated approach to fragment-based lead generation: Philosophy, strategy and case studies from AstraZeneca's drug discovery programmes
-
Albert, J. S.; Blomberg, N.; Breeze, A. L.; Brown, A. J. H.; Burrows, J. N.; Edwards, P. D.; Folmer, R. H. A.; Geschwindner, S.; Griffen, E. J.; Kenny, P. W.; Nowak, T.; Olsson, L.-L.; Sanganee, H.; Shapiro, A. B. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes Curr. Top. in Med. Chem. 2007, 7, 1600-1620
-
(2007)
Curr. Top. in Med. Chem.
, vol.7
, pp. 1600-1620
-
-
Albert, J.S.1
Blomberg, N.2
Breeze, A.L.3
Brown, A.J.H.4
Burrows, J.N.5
Edwards, P.D.6
Folmer, R.H.A.7
Geschwindner, S.8
Griffen, E.J.9
Kenny, P.W.10
Nowak, T.11
Olsson, L.-L.12
Sanganee, H.13
Shapiro, A.B.14
-
14
-
-
2042507954
-
Palladium-catalyzed cross-coupling reactions of organoboron compounds
-
Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds Chem. Rev. 1995, 95, 2457-2483
-
(1995)
Chem. Rev.
, vol.95
, pp. 2457-2483
-
-
Miyaura, N.1
Suzuki, A.2
-
15
-
-
0033843143
-
The Suzuki, the Heck, and the Stille reaction - Three versatile methods, for the introduction of new C-C bonds on solid support
-
Franzen, R. The Suzuki, the Heck, and the Stille reaction; three versatile methods for the introduction of new C-C bonds on solid support Can. J. Chem. 2000, 78, 957-962 (Pubitemid 30666815)
-
(2000)
Canadian Journal of Chemistry
, vol.78
, Issue.7
, pp. 957-962
-
-
Franzen, R.1
-
16
-
-
85077634689
-
The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products
-
Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products Synthesis 1981, 1, 1-28
-
(1981)
Synthesis
, vol.1
, pp. 1-28
-
-
Mitsunobu, O.1
-
17
-
-
45949123116
-
Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin
-
Rink, H. Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin Tetrahedron Lett. 1987, 28, 3787-3790
-
(1987)
Tetrahedron Lett.
, vol.28
, pp. 3787-3790
-
-
Rink, H.1
-
18
-
-
26444475360
-
Selective alkylation of a 6,7-dihydroxyquinazoline
-
DOI 10.1016/j.tetlet.2005.09.038, PII S0040403905019945
-
Harris, C. S.; Hennequin, L. F.; Kettle, J. G.; Willerval, O. A. Selective alkylation of a 6,7-dihydroxyquinazoline Tetrahedron Lett. 2005, 46, 7715-7719 (Pubitemid 41430316)
-
(2005)
Tetrahedron Letters
, vol.46
, Issue.45
, pp. 7715-7719
-
-
Harris, C.S.1
Hennequin, L.F.2
Kettle, J.G.3
Willerval, O.A.4
-
19
-
-
60549101738
-
Three-point variation of a gefinitib quinazoline core
-
Harris, C. S.; Hennequin, L. F.; Willerval, O. A. Three-point variation of a gefinitib quinazoline core Tetrahedron Lett. 2009, 50, 1600-1602
-
(2009)
Tetrahedron Lett.
, vol.50
, pp. 1600-1602
-
-
Harris, C.S.1
Hennequin, L.F.2
Willerval, O.A.3
-
21
-
-
84883489712
-
From split-mix to discrete
-
Furka, A. From split-mix to discrete Comb. Chem. Technol. 2005, 2) 7-32
-
(2005)
Comb. Chem. Technol.
, Issue.2
, pp. 7-32
-
-
Furka, A.1
|